登录 | 注册    关注公众号  
微信公众号
搜索
 >  Kits>Fc gamma RIIA / CD32a >FRT-05

Human Fc gamma RIIA / CD32a (R167) binding Kit (TR-FRET)

For research use only.

优势与特点(FAB)

  1. Cost effective - Sufficient quantity at a lower price, accounting for dilution and pipetting losses.
  2. Comprehensive validation - Validated with various antibody subtypes and antibody drugs.
  3. Simple and fast operation - No complicated washing steps, significantly reducing time.
  4. High batch consistency - Strict control over raw materials and finished product quality, ensuring a stable supply.
  5. Accurate and reliable results - High sensitivity with minimal matrix effects.
  6. High throughput capability - Supports 500 tests, ideal for high-throughput screening.
  7. Fast completion - Results in just 1 hour.

产品参数(Product Specifications)

Assay TypeInhibition-TR-FRET
AnalyteHuman IgG, Human IgG Fc protein, Anti-human CD32a antibody
Format100T/500T
ReactivityHuman
Regulatory StatusRUO
SensitivityIC50=816.6nM
Standard Curve Range2.4414 nM-10000 nM
Assay Time1 hr
Suitable Sample TypeFor the binding of IgG Fc region to the human CD32a
Sample volume10 μL

产品概述(Product Overview)

The Human Fc gamma RIIA / CD32a (R167) binding Kit (TR-FRET) is based on a homogeneous (no wash) competition TR-FRET technology (Time-Resolved Fluorescence Resonance Energy Transfer) to measure the interaction between human CD32a (R167) and antibody drug candidates or CD32a (R167) inhibitors. It is designed to facilitate the ADCC and ADCP functional performance evaluation of antibody drug candidates, high-throughput screening of CD32a (R167) inhibitors within 0.5-1 hours. It can also be used as a universal detection tool to identify the ability of antibody drugs to bind to human CD32a (R167).

存储(Storage)

1. Unopened kit should be stored at 2℃-8℃ upon receiving.

2. Find the expiration date on the outside packaging and do not use reagents past their expiration date.

3. The opened kit should be stored per components table. The shelf life is 30 days from the date of opening.

组分(Materials Provided)

IDComponentsSize
FRT05-C01Human Fc gamma RIIA / CD32a (R167) Protein Europium-chelate100 tests/500 tests
FRT05-C02FA labeled human IgG antibody100 tests/500 tests
FRT05-C03Human IgG Standard400 μg/100 tests
2000 μg/500 tests
FRT05-C04Sample Dilution Buffer10 mL/100tests & 500tests
FRT05-C05Detection Buffer10 mL/100tests & 500tests

原理(Assay Principles)

Human Fc gamma RIIA / CD32a (R167) binding kit (TR-FRET) is based on TR-FRET technology (Time-Resolved Fluorescence Resonance Energy Transfer). Use the mixture of biotinylated human Fc gamma RIIA / CD32a (R167) and Europium-chelate labeled streptavidin as the donor, FA labeled Human IgG1 antibody as the acceptor.

- In the absence of human Fc gamma RIIA/CD32a (R167) binding components, the donor and acceptor are in close proximity due to the binding of human Fc gamma RIIA/CD32a (R167) and FA-labeled Human IgG1 antibody. Upon excitation with a specific light source, the donor emits a 620 nm signal, which is absorbed by the acceptor, resulting in a 665 nm emission.

- In the presence of human Fc gamma RIIA/CD32a (R167) binding components, they disrupt the donor-acceptor interaction, preventing FRET from occurring.

Assay Principles

质量管理控制体系(QMS)

  1. 质量管理体系(ISO, GMP)
  2. 质量优势
  3. 质控流程
 

活性(Bioactivity)-TR-FRET Please refer to DS document for the assay protocol.

Fc gamma RIIA / CD32a TR-FRET

Inhibition Assay of interaction of Europium-chelate labeled human Fc gamma RIIA / CD32a (R167) and FA labeled human lgG by Human IgG standard in a homogeneous (no wash) TR-FRET (Time-Resolved Fluorescence Resonance Energy Transfer) competition assay, with a typical IC50 of 913 nM (QC tested).

Fc gamma RIIA / CD32a TR-FRET

The kit has been used to detect different subclasses of Human IgG (Human IgG1, Human IgG2, Human IgG3 and Human IgG4), which exhibit different IC50 results as expected. As shown in the following figure, human CD32a (R167) binds to human IgG1, IgG2, IgG3 and IgG4 with low affinity.

Fc gamma RIIA / CD32a TR-FRET

The kit has been used to detect different subclasses of mouse IgG (mouse IgG1, mouse IgG2a and mouse IgG2b), which exhibit different IC50 results as expected. As shown in the figure, human CD32a (R167) binds to mouse IgG1, mouse IgG2a, and mouse IgG2b with low affinity as observed, and mouse IgG1 show the higher affinity than mouse IgG2a or mouse IgG2b.

Fc gamma RIIA / CD32a TR-FRET

The kit has been used to detect four FDA approved antibody drugs with different affinities binding to human CD32a (R167). Bevacizumab, Toripalimab, Eculizumab and Efgartigimod alfa bind to human CD32a (R167) with the low affinity from 1 μM to 10 μM.

Fc gamma RIIA / CD32a TR-FRET

Verify potential matrix effects by adding different levels of DEME, RPMI1640, FBS and HSA to the Sample Diluted buffer.

 
评论(0)
 
ACRO质量管理体系
 
 

背景(Background):Fc gamma RIIA / CD32a

Receptors for the Fc region of IgG (Fc γ R) are members of the Ig superfamily that function in the activation or inhibition of immune responses. Three classes of human Fc γ Rs: RI (CD64), RII (CD32), and RIII (CD16), which generate multiple isoforms, are recognized.
There are three genes for human Fcγ RII /CD32 (A, B, and C) and one for mouse Fcγ RII B (CD32B). CD32 is a low affinity receptor for IgG. The activating isoform, CD32A, is expressed on monocytes, neutrophils, platelets and dendritic cells. CD32A is expressed on many immune cell types (macrophage, neutrophil, eosinophils, platelets, dendritic cells and Langerhan cells), where inhibitory ITIM­bearing receptors may also be coexpressed and co­engaged by specific ligands. CD32A delivers an activating signal upon ligand binding, and results in the initiation of inflammatory responses including cytolysis, phagocytosis, degranulation and cytokine production. The responses can be modulated by signals from the coexpressed inhibitory receptors such as CD32B

 

前沿进展

FcRγIIA attenuates pathology of cutaneous leishmaniasis and modulates ITAMa/i balance
Hammi, Giron-Michel, Riyad et al
Parasit Vectors (2024) 17 (1), 517
Abstract: Leishmania is the causal parasite of leishmaniasis, a neglected tropical disease affecting millions of individuals worldwide, and its dissemination is linked to climate change. Despite the complexity and effectiveness of the immune response, the parasite has developed many strategies to evade it and take control of the host cell to replicate. These evasion strategies start at early stages of infection by hijacking immune receptors to mitigate the cellular response. In this study, we examined whether Leishmania uses the Fc receptor FcγRIIA/CD32a and its downstream signaling pathways to evade the host immune response.Regarding in vivo studies, CD32a transgenic mice and the corresponding wild types were infected with Leishmania major Friedlin strain. For the in vitro experiments, BMDMs isolated from WT or CD32a transgenic mice and control or CD32a knockdown differentiated THP-1s were infected with two species of Leishmania, Leishmania major and L. tropica.In vivo, expression of FcγRIIA/CD32a was found to accelerate the signs of inflammation while simultaneously preventing the formation of necrotic lesions after Leishmania infection. In infected macrophages, the presence of FcγRIIA/CD32a did not affect the secretion of proinflammatory cytokines, while the balance between ITAMa and ITAMi proteins was disturbed with improved Fyn and Lyn activation. Unexpectedly, infection with L. tropica but not L. major triggered an intracytoplasmic processing of FcγRIIA/CD32a.Our observations underscore the significance of FcγRIIA/CD32a in cutaneous leishmaniasis and its potential use as a therapeutic target.© 2024. The Author(s).
Genetic variation of FcγRIIa induces higher uptake of Leishmania infantum and modulates cytokine production by adherent mononuclear cells in vitro
Catarino, de Oliveira, Silva et al
Front Immunol (2024) 15, 1343602
Abstract: Single nucleotide variations (SNVs) are specific genetic variations that commonly occur in a population and often do not manifest phenotypically. However, depending on their location and the type of nucleotide exchanged, an SNV can alter or inhibit the function of the gene in which it occurs. Immunoglobulin G (IgG) receptor genes have exhibited several polymorphisms, including rs1801274, which is found in the FcgRIIa gene. The replacement of A with T results in a Histidine (H) to Arginine (R) substitution, altering the affinity of the IgG receptor for IgG subtypes and C-reactive protein (CRP). In this study, we analyzed rs1801274 and its functional implications concerning L. Infantum uptake and cytokine production.We genotyped 201 individuals from an endemic area for visceral leishmaniasis to assess the presence of rs1801274 using Taqman probes for a candidate gene study. Additionally, we included seventy individuals from a non-endemic area for a functional study. Subsequently, we isolated and cultivated one-week adherent mononuclear cells (AMCs) derived from the peripheral blood of participants residing in the non-endemic region in the presence of L. infantum promastigotes, with and without antigen-specific IgG and/or CRP. We analyzed the rate of phagocytosis and the production of nitric oxide (NO), tumor necrosis factor (TNF)-a, interleukin (IL)-10, IL-12 p70, IL-1b, IL- 6, and IL-8 in the culture supernatants.In participants from the endemic region, the A/G (H/R isoform) heterozygous genotype was significantly associated with susceptibility to the disease. Furthermore, SNVs induced a change in the phagocytosis rate in an opsonin-dependent manner. Opsonization with IgG increased the production of IL-10, TNF-a, and IL-6 in AMCs with the H/R isoform, followed by a decrease in NO production. The results presented here suggest that the rs1801274 polymorphism is linked to a higher susceptibility to visceral leishmaniasis.Copyright © 2024 Catarino, Oliveira, Silva, Sales-Campos, de Vito, Silva, Naves, Oliveira, Rodrigues and Rodrigues.
Function-structure approach reveals novel insights on the interplay of Immunoglobulin G 1 proteoforms and Fc gamma receptor IIa allotypes
Lippold, Mistry, Lenka et al
Front Immunol (2023) 14, 1260446
Abstract: Human Fc gamma receptor IIa (FcγRIIa) or CD32a has two major allotypes with a single amino acid difference at position 131 (histidine or arginine). Differences in FcγRIIa allotypes are known to impact immunological responses such as the clinical outcome of therapeutic monoclonal antibodies (mAbs). FcγRIIa is involved in antibody-dependent cellular phagocytosis (ADCP), which is an important contributor to the mechanism-of-action of mAbs by driving phagocytic clearance of cancer cells. Hence, understanding the impact of individual mAb proteoforms on the binding to FcγRIIa, and its different allotypes, is crucial for defining meaningful critical quality attributes (CQAs). Here, we report a function-structure based approach guided by novel FcγRIIa affinity chromatography-mass spectrometry (AC-MS) assays to assess individual IgG1 proteoforms. This allowed to unravel allotype-specific differences of IgG1 proteoforms on FcγRIIa binding. FcγRIIa AC-MS confirmed and refined structure-function relationships of IgG1 glycoform interactions. For example, the positive impact of afucosylation was higher than galactosylation for FcγRIIa Arg compared to FcγRIIa His. Moreover, we observed FcγRIIa allotype-opposing and IgG1 proteoform integrity-dependent differences in the binding response of stress-induced IgG1 proteoforms comprising asparagine 325 deamidation. The FcγRIIa-allotype dependent binding differences resolved by AC-MS were in line with functional ADCP-surrogate bioassay models. The molecular basis of the observed allotype specificity and proteoform selectivity upon asparagine 325 deamidation was elucidated using molecular dynamics. The observed differences were attributed to the contributions of an inter-molecular salt bridge between IgG1 and FcγRIIa Arg and the contribution of an intra-molecular hydrophobic pocket in IgG1. Our work highlights the unprecedented structural and functional resolution of AC-MS approaches along with predictive biological significance of observed affinity differences within relevant cell-based methods. This makes FcγRIIa AC-MS an invaluable tool to streamline the CQA assessment of therapeutic mAbs.Copyright © 2023 Lippold, Mistry, Lenka, Whang, Liu, Pitschi, Kuhne, Reusch, Cadang, Knaupp, Izadi, Dunkle, Yang and Schlothauer.
FcγRIIA-specific DARPins as novel tools in blood cell analysis and platelet aggregation
Riechert, Hein, Visser et al
J Biol Chem (2023) 299 (6), 104743
Abstract: Fc receptors are involved in a variety of physiologically and disease-relevant responses. Among them, FcγRIIA (CD32a) is known for its activating functions in pathogen recognition and platelet biology, and, as potential marker of T lymphocytes latently infected with HIV-1. The latter has not been without controversy due to technical challenges complicated by T-B cell conjugates and trogocytosis as well as a lack of antibodies distinguishing between the closely related isoforms of FcγRII. To generate high-affinity binders specific for FcγRIIA, libraries of designed ankyrin repeat proteins (DARPins) were screened for binding to its extracellular domains by ribosomal display. Counterselection against FcγRIIB eliminated binders cross-reacting with both isoforms. The identified DARPins bound FcγRIIA with no detectable binding for FcγRIIB. Their affinities for FcγRIIA were in the low nanomolar range and could be enhanced by cleavage of the His-tag and dimerization. Interestingly, complex formation between DARPin and FcγRIIA followed a two-state reaction model, and discrimination from FcγRIIB was based on a single amino acid residue. In flow cytometry, DARPin F11 detected FcγRIIA+ cells even when they made up less than 1% of the cell population. Image stream analysis of primary human blood cells confirmed that F11 caused dim but reliable cell surface staining of a small subpopulation of T lymphocytes. When incubated with platelets, F11 inhibited their aggregation equally efficient as antibodies unable to discriminate between both FcγRII isoforms. The selected DARPins are unique novel tools for platelet aggregation studies as well as the role of FcγRIIA for the latent HIV-1 reservoir.Copyright © 2023 The Authors. Published by Elsevier Inc. All rights reserved.
Showing 1-4 of 50 papers.
Powered by BizGenius
 
 
货号/价格
文档
联系电话:
+86 400-682-2521(全国)
010-53681107(北京)
021-50850665(上海)
运输方式
订单邮箱:
order.cn@acrobiosystems.com
技术支持邮箱:
tech.cn@acrobiosystems.com
Fc gamma RIIA / CD32a靶点信息
英文全称:Low affinity immunoglobulin gamma Fc region receptor II-a
中文全称:低亲和力免疫球蛋白γFc区受体II-a
种类:Homo sapiens
上市药物数量:0详情
临床药物数量:2详情
最高研发阶段:临床一期
查看更多信息
前沿进展
点击查看详细

消息提示

请输入您的联系方式,再点击提交!

确定